This Phase 1 clinical trial, sponsored by Wyeth (a subsidiary of Pfizer), investigates the effects of Lecozotan SR on cardiac repolarization in healthy adults. The study's completion in August 2007 indicates that the asset has progressed through initial safety and pharmacokinetic evaluations. Given the increasing focus on cardiac safety in drug development, particularly for CNS-active compounds, Lecozotan SR may have potential applications in treating conditions like Alzheimer's disease, where cardiac safety is paramount. The competitive landscape includes other 5-HT1A antagonists, and successful outcomes could position Lecozotan SR favorably in the market, especially if it demonstrates a favorable safety profile compared to existing therapies.